Rafee Talukder

TL;DR: In this article , the authors found that the presence of liver/bone metastases would be associated with worse outcomes with immune checkpoint inhibitors (ICI) in urothelial carcinoma (aUC).

TL;DR: In this paper , the authors examined patient and disease characteristics, toxicity, and clinical outcomes for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune checkpoint inhibitor (ICI)-based therapy.

TL;DR: In this article , the authors performed a retrospective multi-institution cohort study in patients with advanced urothelial carcinoma (aUC) treated with 1L platinum-based chemotherapy, who received 2L ICI.

TL;DR: In this paper, the authors compared clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease.

TL;DR: PSMA PET may impact decision making in patients with BCR after treatment of localized prostate cancer, particularly for those with equivocal findings on conventional imaging, regardless of clinical risk at diagnosis.